Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;80(1):85-90.
doi: 10.1007/s40265-019-01251-5.

Luspatercept: First Approval

Anthony Markham  1
Affiliations
Review

Luspatercept: First Approval

Anthony Markham. Drugs. 2020 Jan.

Abstract

Luspatercept (REBLOZYL®) is an erythroid maturation agent developed by Acceleron Pharma and Celgene Corporation for the treatment of anaemia associated with myelodysplastic syndromes, myelofibrosis and beta-thalassaemia. Based primarily on the results of the phase III BELIEVE trial, subcutaneous luspatercept was recently approved in the USA for the treatment of anaemia associated with beta-thalassaemia. This article summarizes the milestones in the development of luspatercept leading to this first approval.

PubMed Disclaimer

References

    1. Nat Med. 2014 Apr;20(4):408-14 - PubMed
    1. Lancet Oncol. 2017 Oct;18(10):1338-1347 - PubMed
    1. Blood. 2019 Feb 21;133(8):790-794 - PubMed
    1. Blood. 2019 Mar 21;133(12):1279-1289 - PubMed

MeSH terms

LinkOut - more resources